CAS: 144690-92-6 - Triphenyl Methyl Olmesartan
Formula:C48H44N6O6
InChI:InChI=1S/C48H44N6O6/c1-5-17-41-49-43(47(3,4)57)42(45(55)58-31-40-32(2)59-46(56)60-40)53(41)30-33-26-28-34(29-27-33)38-24-15-16-25-39(38)44-50-51-52-54(44)48(35-18-9-6-10-19-35,36-20-11-7-12-21-36)37-22-13-8-14-23-37/h6-16,18-29,57H,5,17,30-31H2,1-4H3
InChI key:InChIKey=IJOPLMOXIPGJIJ-UHFFFAOYSA-N
SMILES:O=C1OC(=C(O1)COC(=O)C2=C(N=C(N2CC=3C=CC(=CC3)C=4C=CC=CC4C5=NN=NN5C(C=6C=CC=CC6)(C=7C=CC=CC7)C=8C=CC=CC8)CCC)C(O)(C)C)C
- Synonyms:
- (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1-trityl-1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylate
- 1,3-Dioxole, 1H-imidazole-5-carboxylic acid deriv.
- 1H-Imidazole-5-carboxylic acid,4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-,(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester
- 5-Methoxy-2-oxo-1,3-dioxol-4-yl) methyl-4-(1-hydroxy-1-methylethyl-2 propyl-1-(2-(2-triphenylmethyl)-2H-tetrazole-5-yl) biphenyl-4-yl) methyl)-1H-imidazole-5-carboxylate
- Omst-C
- Trityl Olmesartan Medoximil (N-1)
- Trityl Olmesartan Medoxomil
- Trityl olmesartan
- Tritylolmesartan medoxomil
1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester
Ref: IN-DA001K06
1g | 37.00 € | ||
5g | 68.00 € | ||
25g | 180.00 € |
Tritylolmesartan Medoxomil
Ref: TM-T35642
5g | 54.00 € | ||
10g | 85.00 € | ||
25g | 161.00 € | ||
100g | 291.00 € |
4-(1-Hydroxy-1-methylethyl)-2-propyl-1[4-[2-(trityltetrazol-5-yl)phenyl]phenyl]methylimidazo-5-carboxylate (5-methyl-2-oxo-1,3-dioxo len-4-yl)methyl
Ref: 3D-IH57932
10g | 194.00 € | ||
25g | 310.00 € | ||
50g | 436.00 € | ||
100g | 646.00 € | ||
250g | 1,047.00 € |
N1-Trityl Olmesartan Medoxomil
Ref: 4Z-O-0810
10mg | Discontinued | Request information | |
25mg | Discontinued | Request information | |
50mg | Discontinued | Request information | |
100mg | Discontinued | Request information |